The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose The addition of immune checkpoint inhibitors to chemotherapy has improved survival outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC). However, their real-world effectiveness remains unknown. Therefore, we investigated the effectiveness of atezolizumab plus chemotherapy in ES-SCLC in actual clinical settings. Materials and Methods In this multicenter prospective cohort study, patients with ES-SCLC receiving or scheduled to receive atezolizumab in combination with etoposide and carboplatin were enrolled between June 2021 and August 2022. The primary outcomes were progression-free survival (PFS) and the 1-year overall survival (OS) rate. Results A total of 100 patients with ES-SCLC were enrolled from seven centers. Median age was 69 years, and 6% had an Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2. The median PFS was 6.0 months, the 1-year OS rate was 62.2%, and the median OS was 13.5 months. An ECOG PS of 2-3 and progressive disease as the best response were poor prognostic factors for PFS, while an ECOG PS of 2-3 and brain metastasis were associated with poor prognosis for OS. In addition, consolidative thoracic radiotherapy was found to be an independent favorable prognostic factor for OS (hazard ratio, 0.336; p=0.021). Grade ≥ 3 treatment-related adverse events were observed in 7% of patients, with treatment-related deaths occurring in 2% of patients. Conclusion We provided evidence of the favorable real-world effectiveness and safety of atezolizumab plus chemotherapy in ES-SCLC patients, including in the elderly and those with poor ECOG PS. Additional consolidative thoracic radiotherapy may also benefit ES-SCLC patients.
Abstract
Purpose The addition of immune checkpoint inhibitors to chemotherapy has improved survival outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC). However, their real-world effectiveness remains unknown. Therefore, we investigated the effectiveness of atezolizumab plus chemotherapy in ES-SCLC in actual clinical settings. Materials and Methods In this multicenter prospective cohort study, patients with ES-SCLC receiving or scheduled to receive atezolizumab in combination with etoposide and carboplatin were enrolled between June 2021 and August 2022. The primary outcomes were progression-free survival (PFS) and the 1-year overall survival (OS) rate. Results A total of 100 patients with ES-SCLC were enrolled from seven centers. Median age was 69 years, and 6% had an Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2. The median PFS was 6.0 months, the 1-year OS rate was 62.2%, and the median OS was 13.5 months. An ECOG PS of 2-3 and progressive disease as the best response were poor prognostic factors for PFS, while an ECOG PS of 2-3 and brain metastasis were associated with poor prognosis for OS. In addition, consolidative thoracic radiotherapy was found to be an independent favorable prognostic factor for OS (hazard ratio, 0.336; p=0.021). Grade ≥ 3 treatment-related adverse events were observed in 7% of patients, with treatment-related deaths occurring in 2% of patients. Conclusion We provided evidence of the favorable real-world effectiveness and safety of atezolizumab plus chemotherapy in ES-SCLC patients, including in the elderly and those with poor ECOG PS. Additional consolidative thoracic radiotherapy may also benefit ES-SCLC patients.
참고문헌 (28)
- Miller KD, "Cancer treatment and survivorship statistics, 2022", CA Cancer J Clin, 72, pp.409~436 (2022)
- Kim HC, "Clinical characteristics and prognostic factors of lung cancer in Korea : a pilot study of data from the Korean Nationwide Lung Cancer Registry", Tuberc Respir Dis(Seoul), 82, pp.118~125 (2019)
- Rudin CM, "Small-cell lung cancer", Nat Rev Dis Primers, 7, pp.3~ (2021)
- Spigel DR, "Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer : results from the SALUTE trial", J Clin Oncol, 29, pp.2215~2222 (2011)
- Fukuoka M, "Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer", J Natl Cancer Inst, 83, pp.855~861 (1991)
- Baka S, "Phase III randomised trial of doxorubicinbased chemotherapy compared with platinum-based chemotherapy in small-cell lung cancer", Br J Cancer, 99, pp.442~447 (2008)
- Socinski MA, "Phase III study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapynaive patients with extensive-stage small-cell lung cancer", J Clin Oncol, 27, pp.4787~4792 (2009)
- Farago AF, "Current standards for clinical management of small cell lung cancer", Transl Lung Cancer Res, 7, pp.69~79 (2018)
- Horn L, "First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer", N Engl J Med, 379, pp.2220~2229 (2018)
- Peifer M, "Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer", Nat Genet, 44, pp.1104~1110 (2012)
- Rizvi NA, "Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer", Science, 348, pp.124~128 (2015)
- Paz-Ares L, "Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer(CASPIAN) : a randomised, controlled, open-label, phase 3 trial", Lancet, 394, pp.1929~1939 (2019)
- Rudin CM, "Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage smallcell lung cancer : randomized, double-blind, phase III KEYNOTE-604 study", J Clin Oncol, 38, pp.2369~2379 (2020)
- "Small cell lung cacner (version 3.2023)" (2023)[URL]
- Kim SH, "Realworld evaluation of atezolizumab and etoposide-carboplatin as a first-line treatment for extensive-stage small cell lung cancer", Korean J Intern Med, 38, pp.218~225 (2023)
- Sagie S, "Real-world evidence for immunotherapy in the first line setting in small cell lung cancer", Lung Cancer, 172, pp.136~141 (2022)
- Elegbede AA, "A real-world evaluation of atezolizumab plus platinum-etoposide chemotherapy in patients with extensivestage SCLC in Canada", JTO Clin Res Rep, 2, pp.100249~ (2021)
- Gaspar LE, "Small-cell lung cancer : prognostic factors and changing treatment over 15 years", Clin Lung Cancer, 13, pp.115~122 (2012)
- Ma X, "Prognostic factor analysis of patients with small cell lung cancer : realworld data from 988 patients", Thorac Cancer, 12, pp.1841~1850 (2021)
- Sperduto PW, "Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases : a multi-institutional analysis of 4, 259 patients", Int J Radiat Oncol Biol Phys, 77, pp.655~661 (2010)
- Bremnes RM, "The value of prognostic factors in small cell lung cancer : results from a randomised multicenter study with minimum 5 year follow-up", Lung Cancer, 39, pp.303~313 (2003)
- Slotman BJ, "Use of thoracic radiotherapy for extensive stage small-cell lung cancer : a phase 3 randomised controlled trial", Lancet, 385, pp.36~42 (2015)
- Rathod S, "Role of thoracic consolidation radiation in extensive stage small cell lung cancer : a systematic review and meta-analysis of randomised controlled trials", Eur J Cancer, 110, pp.110~119 (2019)
- Tang C, "Combining radiation and immunotherapy : a new systemic therapy for solid tumors?", Cancer Immunol Res, 2, pp.831~838 (2014)
- Ou SH, "Prognostic factors for survival in extensive stage small cell lung cancer(ED-SCLC) : the importance of smoking history, socioeconomic and marital statuses, and ethnicity", J Thorac Oncol, 4, pp.37~43 (2009)
- "Coronavirus disease (COVID-19) weekly epidemiological updates and monthly operational updates" (2023)[URL]
- "The updates of COVID-19 in Republic of Korea" (2023)[URL]
- Ragavan MV, "Analysis of serious adverse event reporting for patients enrolled in cancer clinical trials during the COVID-19 pandemic", JAMA Oncol, 8, pp.1849~1851 (2022)